Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 61 EV-to-FCF is -20.01 as of Jul. 14, 2026. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.16 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 1010100% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pangaea Oncology's Enterprise Value is €59.90 Mil.
Pangaea Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.99 Mil. Therefore, Pangaea Oncology's EV-to-FCF for today is -20.01.
The historical rank and industry rank for Pangaea Oncology's EV-to-FCF or its related term are showing as below:
XMAD:PANG'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.24 Med: -13.95 Max: -3.87
Current: -20.01
During the past 13 years, the highest EV-to-FCF of Pangaea Oncology was -3.87. The lowest was -27.24. And the median was -13.95.
XMAD:PANG's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs XMAD:PANG: -20.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pangaea Oncology's PE Ratio (TTM) for today is calculated as:
Pangaea Oncology's share price for today is €1.57.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pangaea Oncology EV-to-FCF Related Terms
Pangaea Oncology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Pangaea Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's EV-to-FCF falls into.
Pangaea Oncology's current Enterprise Value is €59.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a EV-to-FCF of -20.01 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is Pangaea Oncology's EV-to-FCF too high?
Pangaea Oncology's current EV-to-FCF is -20.01. Based on the distribution chart, Pangaea Oncology ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #999999 out of 99 companies for EV-to-FCF. This places Pangaea Oncology in the lower half of its industry. The industry median EV-to-FCF is 25.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current EV-to-FCF is -20.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.16, compared to a current price of €1.57 — trading 27.3% below its estimated fair value. The current EV-to-FCF is -20.01. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current EV-to-FCF is -20.01 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.57 is trading 27.3% below its estimated GF Value™ of €2.16.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
EV-to-FCF: -20.01
GF Value™: €2.16 vs. price of €1.57 (27.3% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score
Get the complete analysis for XMAD:PANG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
